4th Quarter - Report

THE UNITED STATES PHARMACOPEIAL CONVENTION for THE UNITED STATES PHARMACOPEIAL CONVENTION

Firm
Client
Income
—
Expenses
$100,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

H.R. 5304, S.2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; H.R. 4779 National Security, Department of State, and Related Programs Appropriations Act, 2026: Provisions related to pharmaceutical supply chain resilience.

LobbyistCovered position, as disclosed
TIMOTHY J CASEY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5304 (119th), S. 2587 (119th), H.R. 4779 (119th)

Defense DEF

S. 2296 - National Defense Authorization Act for Fiscal Year 2026: Provisions regarding medicine supply chain.

LobbyistCovered position, as disclosed
TIMOTHY J CASEY —

Contacted: SENATE

Bills named: S. 2296 (119th)

Health Issues HCR

S. 1784 - Mapping America's Pharmaceutical Supply (MAPS) Act; H.R. 4191: Provisions regarding supply chain security and resilience and drug shortages.

LobbyistCovered position, as disclosed
TIMOTHY J CASEY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4191 (119th), S. 1784 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.